Qualigen Therapeutics Secures Nasdaq Compliance After $4.5M Private Placement

Qualigen Therapeutics recently averted delisting from Nasdaq by raising $4.5 million through a private placement of Series A-3 Preferred Stock, which restored compliance with Nasdaq's minimum stockholders’ equity requirement. The company filed its delayed Q1 2025 10-Q and submitted a 12-month compliance plan accepted by Nasdaq, demonstrating a commitment to maintaining listing standards. Despite these positive steps, financial challenges persist, including declining revenue and losses, leading some analysts to rate the stock as an underperform with cautious outlooks. The private placement's convertible feature offers flexibility for future fundraising but may dilute existing shareholders. Qualigen specializes in developing novel therapeutics for cancer and infectious diseases, with a pipeline addressing high unmet medical needs. Overall, while the capital raise and compliance efforts signal operational resilience, the company faces an uncertain path toward long-term viability in a volatile biotech sector.